Summit Corporation plc
("Summit plc" or "the Company")
ADDITIONAL LISTING
Oxford, UK, 25 March 2008 - Summit Corporation plc (AIM: SUMM), a leading UK biotechnology company, announces an application has been made to the Alternative Investment Market of the London Stock Exchange ("AIM") for 1,173,233 new ordinary shares of 10p each in the Company ("Ordinary Shares") to be admitted to trading on AIM.
The new Ordinary Shares which rank pari passu with the Company's existing Ordinary Shares and have been allotted as deferred consideration of the sale and purchase agreement of DanioLabs Limited dated 21 March 2007. Dealings on AIM are expected to commence on 27 March 2008.
- ENDS -
For more information, please contact:
Summit plc
Steven Lee, PhD, Chief Executive Officer
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations
Steven Lee, PhD, Chief Executive Officer
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations
Tel: +44 (0)1235 443951
Citigate Dewe Rogerson
Mark Swallow, PhD / David Dible / Sylvie Berrebi
Mark Swallow, PhD / David Dible / Sylvie Berrebi
Tel: +44 (0)207 638 9571
Panmure Gordon
Andrew Burnett / Rakesh Sharma
Andrew Burnett / Rakesh Sharma
Tel: +44 (0)207 459 3600
About Summit plc
Summit plc is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company's internal drug development programmes are underpinned by its advanced carbohydrate chemistry and zebrafish drug screening technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.
Summit plc has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neurological disorders, anti-infectives, ophthalmic diseases and oncology.
Summit plc's in-house drug development capabilities combine world-class expertise in both carbohydrate chemistry with high-volume, high-content screening using its proprietary zebrafish technologies. These whole organism screens have the potential to dramatically decrease the time and cost of drug discovery and development by delivering data that are highly predictive of the efficacy and toxicity of potential drug compounds in humans.
The company listed on the AIM market of the London Stock Exchange in October 2004 - symbol: SUMM
Further information about the company is available at www.summitplc.com